home / stock / glaxf / glaxf news


GLAXF News and Press, GlaxoSmithKline Plc From 01/09/24

Stock Information

Company Name: GlaxoSmithKline Plc
Stock Symbol: GLAXF
Market: OTC
Website: gsk.com

Menu

GLAXF GLAXF Quote GLAXF Short GLAXF News GLAXF Articles GLAXF Message Board
Get GLAXF Alerts

News, Short Squeeze, Breakout and More Instantly...

GLAXF - International Wide-Moat Stocks On Sale - The January 2024 Heat Map

2024-01-09 18:04:24 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

GLAXF - GSK plc (GSK) 42nd Annual JP Morgan Healthcare Conference (Transcript)

2024-01-09 14:38:04 ET GSK plc (GSK) 42nd Annual JP Morgan Healthcare Conference January 09, 2024 10:30 AM ET Company Participants Emma Walmsley - Chief Executive Officer Luke Miels - Chief Commercial Officer Tony Wood - Chief Scientific Officer Conference ...

GLAXF - AbbVie Vs. GSK: Dual Dominance In Pharma

2023-12-23 04:18:53 ET Summary AbbVie and GSK are both solid investment choices in the biopharmaceutical industry. AbbVie's financials and forward outlook show strong performance alongside solid partnerships, which hint at growth potential. GSK's current financials, product la...

GLAXF - GSK - Greenshoots In The Horizon

2023-12-13 12:51:53 ET Summary GSK's diversified portfolio and high dividend yield make it an attractive option for conservative value portfolios. The company's pipeline of drugs is improving, with a significant increase in drugs in clinical development and strong financial result...

GLAXF - International Wide-Moat Stocks On Sale - The December 2023 Heat Map

2023-12-05 22:50:05 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

GLAXF - GSK plc (GSK) Getting Ahead of Respiratory Diseases Event with GSK Management Conference (Transcript)

2023-11-30 12:52:09 ET GSK plc (GSK) Getting Ahead of Respiratory Diseases Event with GSK Management Conference Call November 30, 2023 08:00 ET Company Participants Nick Stone - Investor Relations Tony Wood - Chief Scientific Officer Luke Miels - Chief Commercial...

GLAXF - GSK plc (GSK) Presents at Redburn Atlantic CEO Conference (Transcript)

2023-11-29 15:16:06 ET GSK plc (GSK) Redburn Atlantic CEO Conference November 29, 2023 04:00 AM ET Company Participants Luke Miels - Chief Commercial Officer Conference Call Participants Simon Baker - Redburn Presentation Simon Baker Good ...

GLAXF - Biogen: LAQEMBI's $10 Billion Potential

2023-11-29 15:00:01 ET Summary Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar risks; as a result, shares are down over 20% year-over-y...

GLAXF - GSK plc (GSK) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)

2023-11-29 12:33:02 ET GSK plc (GSK) 6th Annual Evercore ISI HealthCONx Conference November 29, 2023 07:30 AM ET Company Participants Jeff McLaughlin - Director, Investor Relations Philip Dormitzer - SVP and Global Head, Vaccines R&D and Infectious Disease Resear...

GLAXF - Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL

2023-11-10 14:23:48 ET Summary Lyell Immunopharma results from a phase 1 study using LYL797 for the treatment of relapsed/refractory NSCLC and TNBC patients with ROR1 expression expected in the 1st half of 2024. Results from phase 1 study using LYL845 for the treatment of patients...

Previous 10 Next 10